Hypertensive chronic kidney disease in African Americans: Strategies for improving care

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 10, 2012, Pages 726-734

  Martins, David ^a   Agodoa, Lawrence ^b   Norris, Keith C ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AFRICAN AMERICAN; ALGORITHM; ARTICLE; CHRONIC KIDNEY FAILURE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; METHODOLOGY; PATHOLOGY; PATIENT CARE; UNITED STATES;

AFRICAN AMERICANS; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; PATIENT CARE; QUALITY OF HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC; UNITED STATES;

EID: 84870272842     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.11109     Document Type: Article

References (36)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
3. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD; National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
4. Norris K, Nissenson AR. Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol 2008;19:1261-1270.
5. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int 2005;68:914-924.
6. Powe NR. To have and have not: health and health care disparities in chronic kidney disease. Kidney Int 2003;64:763-772.
7. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841-845.
8. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
9. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
10. Muntner P, Anderson A, Charleston J, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010;55:441-451.
11. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-713.
12. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-2050.
13. Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003;41:588-595.
14. Luft FC, Grim CE, Fineberg N, Weinberger MC. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation 1979;59:643-650.
15. Chandramohan G, Bai Y, Norris K, Rodriguez-lturbe B, Vaziri ND. Effects of dietary salt on intrarenal angiotensin system, NAD (P) H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys. Am J Nephrol 2008;28:158-167.
16. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 1997;96:2407-2413.
17. Norris KC, Tareen N, Martins D, Vaziri ND. Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. Nat Clin Pract Nephrol 2008;4:538-549.
18. Kao WH, Klag MJ, Meoni LA, et al; Family Investigation of Nephropathy and Diabetes Research Group. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185-1192.
19. Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010;21:1422-1426.
20. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-921.
21. Erratum in N Engl J Med 1994;330:1689.
22. Norris KC, Francis CK. Gender and ethnic differences and considerations in cardiovascular risk assessment and prevention in African Americans. In: Wong N, Gardin JM, Black HR, editors. Practical Strategies in Preventing Heart Disease. New York, NY: McGraw-Hill; 2004:415-440.
23. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431.
24. Erratum in JAMA 2006;295:2726.
25. Wright JT Jr, Agodoa L, Contreras G, et al; African American Study of Kidney Disease and Hypertension Study Group. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002;162:1636-1643.
26. Appel U, Wright JT Jr, Greene T, et al; AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-929.
27. de Zeeuw D, Ramjit D, Zhang Z, et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006;69:1675-1682.
28. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-946.
29. Barrier PA, Li JT, Jensen NM. Two words to improve physician-patient communication: what else? Mayo Clin Proc 2003;78:211-214.
30. Flack JM, Ska DA, Bakris G, et al; International Society on Hypertension in Blacks. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010;56:780-800.
31. Wright JT Jr, Agodoa LY, Appel L, et al. New recommendations for treating hypertension in black patients: evidence and/or consensus? Hypertension 2010;56:801-803.
32. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease: executive summary. Am J Kid Dis 2004;43(suppl 1):S16-S33.
33. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:947-953.
34. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.
35. Martins D, Norris K. Hypertension treatment in African Americans: physiology is less important than sociology. Cleve Clin J Med 2004;71:735-743.
36. Cooper RS, Psaty BM. Should ethnicity serve as the basis for clinical trial design? Diversity and inclusiveness should remain the guiding principles for clinical trials. Circulation 2005;112:3660-3665.